Publisher's Synopsis
The last ten years have seen the publication of a vast amount of data regarding mechanisms of cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential clinical applications of these assays in the treatment of patients with haematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on the role of drug resistance assays in the design and individualization of treatment protocols.;Topics covered include: predictive value of in vitro drug resistance assays, such as the MTT and clonogenic assay, with respect to the clinical outcome; drug resistance profiles, for example for CLL, AMI and non-Hodgkin's lymphomas; functional assays to study drug resistance and clinical correlations; topoisomerase II and drug resistance in leukaemia and lymphoma; prognotic value of MDR1 gene expression in AMI; tailored therapy (chemotherapy based on the results of in vitro drug resistance assays); and modulation of drug resistance.
